A simple, rapid, non-radioactive method for detecting homozygous deletions/conversions of the steroid 21-hydroxylase gene is described. In our experience this method will be useful for first trimester prenatal diagnosis of congenital adrenal hyperplasia in 17% of families of a child with the salt losing form. This test includes an internal control to monitor the success of amplification. 
for the detection of homozygous deletions and gene conversions involving exon 3 of the CYP21B gene, which can be used for the prenatal diagnosis of CAH.
Materials and methods

CLINICAL MATERIAL
Chorionic villus (CVS) and amniocyte cultures were kindly supplied by Mrs E Young, The Hospital for Sick Children, London. They were stored frozen at -20°C until analysed. DNA was isolated from leucocytes and CVS by standard methods.3 4 In addition, samples of CVS and amniocytes were prepared using the rapid method described by Kogan et , lanes 2, 3, 7, 8) and not to the 150 bp band. Conversely the CYP21A specific oligonucleotide hybridised only to those samples which contained the 150 bp band ( fig IC, lanes 1, 3, 4, 5, 6 ). First trimester diagnosis using DNA analysis of chorionic villus biopsy has been reported for CAH arising from a deleted CYP21B gene7 and from undefined defects,' in the latter cases using a combination of probes for 21-hydroxylase, C4, HLA-B, and HLA-DR.
The in vitro amplification method described in this paper can be used in those situations where a homozygous gene deletion or conversion involving exon 3 is present, the loss of the 8 bp fragment in this exon leading to a frameshift mutation and premature termination of mRNA. In our experience the PCR analysis described here is useful in 17% of our patients with classical salt wasting CAH (six of 36). The simultaneous amplification of the CYP21A gene acts as an essential internal control for the amplification process. The third higher molecular weight band seen in normal subjects and non-deleted CAH haplotypes is the result of the formation of heteroduplexes between the CYP21A and CYP21B fragments (unpublished data), heteroduplex formation being a recognised PCR artefact.8 Further tests will define the genetic basis of CAH in other patients.
In view of a recent report that non-pathological point mutations in the primer region can lead to false negative results,9 it would seem prudent to carry out the amplification steps using more than one set of primers. This can easily be accommodated and we would now include an additional amplification of the CYP21B gene alone, using a primer for the region in exon 3 spanning the 8 bp difference. 
